Mangalam Drugs & Organics

₹29.73As of Sun 8 Nov 2026, 12:00 UTC

NSE:MANGALAMHealthcare

Country India

PE (Fwd) —

TSR 10Y CAGR (15.30%)

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.31

PE TTM —

TSR TTM (54.54%)

Mkt cap ₹463.8M

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹33

10.71%

(52.81%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

0.80

(5.73)

4.25

(28.05)

(93.56%)

(816.41%)

174.09%

(760.65%)

Revenue₹B

3.702

3.674

3.176

2.321

(17.89%)

(0.77%)

(13.55%)

(26.90%)

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

2.321

Revenue₹B

—

4.509

3.702

3.674

3.176

2.321

2.154

(15.29%)

(26.90)

Revenue growth%

—

(17.89)

(0.77)

(13.55)

(26.90)

(7.19)

(15.72)

—

31.48

Gross margin%

—

31.22

31.50

32.71

46.41

31.48

31.50

(13.98)

Operating margin%

—

8.61

3.95

0.76

6.16

(13.98)

(14.13)

3.95

(19.13)

Net margin%

—

4.36

0.34

(2.47)

2.12

(19.13)

(19.25)

0.34

—

P/E ratio (avg)x

—

12.04

163.9

—

26.49

—

26.49

—

EV/EBITx

—

6.099

14.22

62.04

9.100

—

11.66

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

(28.05)

EPS₹

—

12.42

0.80

(5.73)

4.25

(28.05)

(26.20)

(30.08%)

—

(760.65)

EPS growth%

—

(93.54)

(814.30)

174.09

(760.65)

6.58

(427.09)

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

15.83

Shares (diluted)M

—

15.83

◌15.83

—

Buyback yield%

—

◌—

—

D/E ratiox

—

0.471

Enterprise value₹B

—

2.366

2.081

1.736

1.780

0.651

0.471

(27.58%)

—

LT debt₹M

—

Peers (US$4.954M)

Cap (US$)

Vaishali Pharma Limited

9.419M

20.01x

Biofil Chemicals and…

5.326M

103.6x

Vivimed Labs Limited

4.777M

—

Newbury Pharmaceutical…

4.948M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(2.644)

1.640

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

23.34

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

3/5

Revenue growth years

0/4

EPS growth years

1/4

Dividend streakyrs

Op margin range%

−14–9

$1 testx

—

Incr. ROIC%

—

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹2.321B

(15.29%)

1.00×

Cost of revenue

₹1.591B

(15.37%)

1.00×

Operating expenses

₹1.055B

0.86%

2.01×

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available